#United States #Philadelphia #Children's Hospital #Garrett Brodeur #Stephan Grupp

Children's Hospital of Philadelphia Celebrates Remarkable Cancer Researchers

The Children's Hospital of Philadelphia (CHOP) has proudly announced that two of its renowned cancer researchers, Dr. Garrett M. Brodeur and Dr. Stephan A. Grupp, have been selected for the esteemed 2025 class of the Fellows of the American Association for Cancer Research (AACR) Academy. This prestigious recognition highlights their significant contributions to the field of cancer research, further demonstrating CHOP’s commitment to advancing pediatric healthcare.

Honoring Dr. Garrett M. Brodeur

Dr. Garrett Brodeur, who serves as the Director of the Cancer Predisposition Program at CHOP and is also a Professor of Pediatrics at the University of Pennsylvania’s Perelman School of Medicine, has been pivotal in advancing the understanding of neuroblastoma. His research has significantly impacted the landscape of pediatric oncology, particularly concerning identifying MYCN amplification as an indicator of high-risk neuroblastoma. His efforts have included leading initiatives to establish the first International Neuroblastoma Staging System, which integrates molecular markers into risk assessments.

Moreover, Dr. Brodeur has organized influential international workshops focused on pediatric cancer predisposition and has pioneered the development of a groundbreaking multivalent nanomedicine, PEEL-24, that promises to be both more effective and less toxic than current treatment options like irinotecan. His work embodies the essence of innovation and dedication required to make real strides in cancer therapies for children.

Acknowledging Dr. Stephan A. Grupp

Dr. Stephan Grupp, the Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at CHOP, has revolutionized the treatment of pediatric cancers through his extensive research in chimeric antigen receptor T-cell (CAR T-cell) therapy. As the Section Chief of Cellular Therapy and Transplant, and a Professor of Pediatrics at the same university, Dr. Grupp has been instrumental in leading revolutionary developments in personalized cancer therapy tailored to young patients.

His groundbreaking work culminated in the FDA approval of tisagenlecleucel for treating B-cell acute lymphoblastic leukemia, marking it as the first CAR T-cell and gene therapy approved for pediatric use. Dr. Grupp's contributions signify a transformative period in cancer treatment, showcasing individualized approaches that directly impact children's health outcomes.

The AACR Academy's Recognition Process

The AACR Academy’s Fellowship is a significant honor that recognizes extraordinary scientists whose work is pivotal to cancer progress. Being inducted as a Fellow involves a rigorous nomination and election process, ensuring that only those who have shown lasting impacts in cancer research are honored in this way. With the induction of Dr. Brodeur and Dr. Grupp, the total number of AACR Academy Fellows rises to 375, reflecting a global coalition of leading experts in cancer research.

The formal induction ceremony will take place at the AACR Annual Meeting, scheduled for April 25-30 in Chicago, Illinois, where both researchers will be celebrated for their groundbreaking contributions.

CHOP's Commitment to Pediatric Care

CHOP, which has held a legacy as the nation's first pediatric hospital since 1855, continues to be a beacon of hope for children battling serious health challenges. The institution's exceptional commitment to patient care, innovative research, and education of future healthcare professionals has facilitated numerous advancements that benefit children worldwide. With one of the largest pediatric research programs in the nation, CHOP remains a leader in the fight against pediatric diseases, consistently embracing family-centered care and community service programs.

To learn more about CHOP and its pioneering efforts in pediatric health, visit www.chop.edu. Safeguarding the health of future generations is not just a commitment; it’s a mission at the Children’s Hospital of Philadelphia.